HOUSTON--(BUSINESS WIRE)--CompanionDx Reference Lab (www.companiondxlab.com), a high-complexity CLIA-certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted NGS and epigenomics testing, today announced Nikko Khazana has joined as senior vice president of sales. In this role, he will lead new business development opportunities, maximize current customer relationships and assist the launch of a commercial multi-therapeutic offering focused on novel and established oncology, specifically next generation DNA sequencing.
“We are extremely excited to have someone of Nikko’s caliber join the team in this role,” said Michael Stewart, CEO of CompanionDx.
“His extensive background in the pharmaceutical-biotech industry and relationships in the market made him a natural fit for this position,” added David Lasecki, president of CompanionDx. “He is a proven leader who can provide direction for business growth, strategic planning and sales.”
Prior to joining CompanionDx, Khazana led the strategy and growth of Cardinal Health Specialty’s Group Purchasing Organization with providers, pharmaceutical and biotech manufacturers. In addition, he led the build-out of Cardinal Health Specialty’s Urology division, which has become the nation’s market share leader in the industry.
Khazana has held various executive management positions in sales, marketing, strategy and operations during the past 20 years within the pharmaceutical-biotech industry. He served as vice president of corporate strategy and services with Supernova, a pharmaceutical marketing agency; vice president and executive director of corporate accounts and new business development with the International Oncology Network (ION), an AmerisourceBergen Specialty Group business; and director of U.S. Radiopharmaceutical Operations with Mallinckrodt, Inc., a Tyco Healthcare business.
Khazana earned a bachelor’s of science degree in pharmacy from the University of Sciences in Philadelphia and extended his marketing and strategy education at Tulane University and University of Notre Dame.
CompanionDx™ Reference Lab is a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted NGS and epigenomics testing. CompanionDx is committed to the next evolution in cancer care where comprehensive genetic data is delivered in an actionable format, thereby enabling the physician to make treatment decisions and choose healthcare strategies based on unique cancer type and the genetic makeup of each patient. CompanionDx’s comprehensive and tumor-specific panels, coupled with personalized pharmacogenomic analysis, provide a unique offering that allows physicians to choose relevant and targeted therapies. For more information visit www.companiondxlab.com.